Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05083429 · ClinicalTrials.gov registry record
Replication of the POET-COPD Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 8,716
- Enrollment target
NCT05083429: Completed study, sponsored by Brigham and Women's Hospital.
NCT05083429 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 8,716 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05083429 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 8,716 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Time to first COPD exacerbation
Interventions
- DRUG Tiotropium
- DRUG Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,716 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2021-08-09 |
What the finished NCT05083429 record still lists
NCT05083429 is an observational study that tracks outcomes without assigning an intervention. Its 8,716 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium is the first listed.
NCT05083429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05083429 about?
NCT05083429 is a clinical study titled "Replication of the POET-COPD Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05083429?
This trial is currently completed. The enrollment target is 8,716 participants. The study started on 2020-09-22. Estimated completion is 2021-08-09.
What interventions are being tested in trial NCT05083429?
The interventions under investigation include: Tiotropium (DRUG), Salmeterol (DRUG).
Who is sponsoring clinical trial NCT05083429?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI